These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27919628)

  • 1. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
    Xu Q; Pryharski K; Pichichero ME
    Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.
    Xu Q; Surendran N; Verhoeven D; Klapa J; Ochs M; Pichichero ME
    Vaccine; 2015 Feb; 33(8):993-1000. PubMed ID: 25597944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.
    Ren D; Almudevar AL; Pichichero ME
    Hum Vaccin Immunother; 2015; 11(2):489-97. PubMed ID: 25692218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
    Verhoeven D; Perry S; Pichichero ME
    Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model.
    Verhoeven D; Xu Q; Pichichero ME
    Vaccine; 2014 May; 32(26):3205-10. PubMed ID: 24731814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.
    Xu Q; Casey JR; Almudevar A; Pichichero ME
    Clin Microbiol Infect; 2017 Jul; 23(7):487.e1-487.e6. PubMed ID: 28143785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
    Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
    Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
    Brooks WA; Chang LJ; Sheng X; Hopfer R;
    Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.
    Visan L; Rouleau N; Proust E; Peyrot L; Donadieu A; Ochs M
    Hum Vaccin Immunother; 2018 Feb; 14(2):489-494. PubMed ID: 29135332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.
    Xu Q; Casey JR; Pichichero ME
    Mucosal Immunol; 2015 Sep; 8(5):1110-7. PubMed ID: 25648056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.
    Almudevar A; Pichichero ME
    Hum Vaccin Immunother; 2017 Oct; 13(10):2316-2321. PubMed ID: 28892455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
    Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
    Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
    Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Otitis-prone Children Have Immunologic Deficiencies in Naturally Acquired Nasopharyngeal Mucosal Antibody Response after Streptococcus pneumoniae Colonization.
    Xu Q; Casey JR; Newman E; Pichichero ME
    Pediatr Infect Dis J; 2016 Jan; 35(1):54-60. PubMed ID: 26448450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
    Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
    Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
    Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
    Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
    Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children.
    Kaur R; Casey JR; Pichichero ME
    Pediatr Infect Dis J; 2011 Aug; 30(8):645-50. PubMed ID: 21487325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media.
    Sabirov A; Metzger DW
    Vaccine; 2006 Jul; 24(27-28):5584-92. PubMed ID: 16730398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.